4.5 Article

Discovery of a Potent and Selective Chikungunya Virus Envelope Protein Inhibitor through Computer-Aided Drug Design

Journal

ACS INFECTIOUS DISEASES
Volume 7, Issue 6, Pages 1503-1518

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.0c00915

Keywords

chikungunya; virtual screening; envelope glycoproteins; entry inhibitors; aminopiperidines and -piperidine analogues

Funding

  1. Agencia Nacional de Promocion Cientifica y Tecnologica, Argentina [PICT 2017-3767]
  2. Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [PIP 2014 11220130100721]

Ask authors/readers for more resources

This study focused on identifying antiviral compounds targeting the E2-E1 envelope glycoprotein complex of CHIKV, resulting in the discovery of compound 11 as a specific inhibitor with improved antiviral activity and low cytotoxicity. Molecular dynamics simulations revealed a potential interaction pattern between compound 11 and the E1-E2 dimer, laying the groundwork for further optimization. The identified binding pocket for compound 11 showed promising antiviral activity and pharmacological profiles, indicating its potential as a CHIKV entry inhibitor.
The worldwide expansion of chikungunya virus (CHIKV) into tropical and subtropical areas in the last 15 years has posed a currently unmet need for vaccines and therapeutics. The E2-E1 envelope glycoprotein complex binds receptors on the host cell and promotes membrane fusion during CHIKV entry, thus constituting an attractive target for the development of antiviral drugs. In order to identify CHIKV antivirals acting through inhibition of the envelope glycoprotein complex function, our first approach was to search for amenable druggable sites within the E2-E1 heterodimer. We identified a pocket located in the interface between E2 and E1 around the fusion loop. Then, via a structure-based virtual screening approach and in vitro assay of antiviral activity, we identified compound 7 as a specific inhibitor of CHIKV. Through a lead optimization process, we obtained compound 11 that demonstrated increased antiviral activity and low cytotoxicity (EC50 1.6 mu M, CC50 56.0 mu M). Molecular dynamics simulations were carried out and described a possible interaction pattern of compound 11 and the E1-E2 dimer that could be useful for further optimization. As expected from target site selection, compound 11 inhibited virus internalization during CHIKV entry. In addition, virus populations resistant to compound 11 included mutation E2-P173S, which mapped to the proposed binding pocket, and second site mutation E1-Y24H. Construction of recombinant viruses showed that these mutations conferred antiviral resistance in the parental background. Finally, compound 11 presents acceptable solubility values and is chemically and enzymatically stable in different media. Altogether, these findings uncover a suitable pocket for the design of CHIKV entry inhibitors with promising antiviral activity and pharmacological profiles.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available